DXCM
Status-Quo-PlayerDexcom
$63.12
-1.40%
as of 13 Apr
Power Core
Dexcom's moat is its clinical accuracy leadership and deep integration into the automated insulin delivery ecosystem, which together create a switching cost that extends across the patient's entire diabetes management stack.
Direction of Movement
Structural Strength Offset by Competitive and Margin Headwinds
ROC 200
-25.0%
DXCM
Dexcom
$63.12
-1.40%
as of 13 Apr
DCF Fair Value: $32.59
Market data unavailable
Company Profile
Dexcom Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management and metabolic health in the United States and internationally. Its CGM systems provide real-time glucose data as an alternative to traditional finger-stick blood glucose testing, enabling better diabetes control for patients and healthcare providers. Key products include the Dexcom G6, an integrated CGM system; Dexcom G7, a next-generation sensor offering 15-day wear time and seamless integration; Dexcom ONE for simplified testing replacement; Dexcom Share for remote monitoring; and Dexcom Real-Time API for third-party app and device integrations. Dexcom Inc. also supports automated insulin delivery through compatibility with insulin pumps from partners like Insulet and Tandem. The company markets directly to endocrinologists, physicians, and diabetes educators, serving people with diabetes across type 1, type 2, and related conditions. Founded in 1999 and headquartered in San Diego, California, Dexcom Inc. plays a pivotal role in advancing real-time glucose monitoring technology within the healthcare sector.